IRIS
PRADA, VALERIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.466
Totale 2.466
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 2.466
Totale 2.466
Salva come PNG Salva come JPEG
Città #
Genova 1.652
Rapallo 430
Genoa 368
Bordighera 13
Vado Ligure 3
Totale 2.466
Salva come PNG Salva come JPEG
Nome #
Sural nerve biopsy and functional studies support the pathogenic role of a novel MPZ mutation. 132
Hyccin, the Molecule Mutated in the Leukodystrophy Hypomyelination and Congenital Cataract (HCC), Is a Neuronal Protein. 118
Hand Rehabilitation Treatment for Charcot-Marie-Tooth Disease: An Open Label Pilot Study 118
Gain of glycosylation: a new pathomechanism of Myelin Protein Zero mutations 115
Innovative quantitative testing of hand function in Charcot-Marie-Tooth neuropathy 114
Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype 110
A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal myofibrillar myopathy 110
Sacral Nerve Stimulation for Fecal Incontinence in a Patient with Antiphospholipid Syndrome- Related Autonomic Neuropathy 108
Immunohistochemical evidnce of HLA-G expression in extravillous trophoblast invading decidual tissues. 101
Testing overwork weakness in Charcot-Marie-tooth disease: Is it true or false? 101
A novel prion protein gene-truncating mutation causing autonomic neuropathy and diarrhea 100
Outcome measures in the clinical evaluation of ambulatory Charcot Marie Tooth 1A subjects 99
Mitochondrial dysfunction in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. 84
Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017 79
GAIN OR LOSS OF GLYCOSYLATION: THE SWEET SIDE OF MYELIN PROTEIN ZERO 74
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 73
Importance of intensive and prolonged rehabilitative treatment on the Guillain-Barrè syndrome long-term outcome: a retrospective study 69
Treadmill training in patients affected by Charcot-Marie-Tooth neuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study 68
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 63
Early detection of external neurological symptoms through a wearable smart-glasses prototype 63
EARLY ONSET DEMYELINATING CHARCOT‐MARIE‐TOOTH DISEASE CAUSED BY A NOVEL IN‐FRAME ISOLEUCINE DELETION IN PERIPHERAL MYELIN PROTEIN 2 60
People with Charcot-Marie-Tooth disease and COVID-19: Impaired physical conditions due to the lockdown. An International cross-sectional survey 58
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 57
Genetic Workup for Charcot–Marie–Tooth Neuropathy: A Retrospective Single-Site Experience Covering 15 Years 55
Comparison of Strength and Dexterity in Professional and Student Violinists: Setting Foundations to Guide Rehabilitation 53
Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years 50
A morphological reappraisal of Tubifex blanchardi Vejdovský, 1891 (Clitellata: Tubificidae) 49
Validation of a new hand function outcome measure in individuals with Charcot-Marie-Tooth disease 43
High-dose immunoglobulin pulse therapy and risk of Covid19 infection 40
NeuroGlasses: A Wearable Prototype for Early Detection of Neurological Symptoms 38
Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale 36
The SPTLC1 p.S331 mutation bridges sensory neuropathy and motor neuron disease and has implications for treatment 34
The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment 34
Charcot-Marie-Tooth neuropathy score and ambulation index are both predictors of orthotic need for patients with CMT 24
A novel mouse model of CMT1B identifies hyperglycosylation as a new pathogenetic mechanism 24
OUTCOMES AFTER SINGLE-CYCLE RITUXIMAB MONOTHERAPY IN PATIENTS WITH ANTI-MAG ANTIBODY POLYNEUROPATHY: A 11 YEARS FOLLOW-UP ANALYSIS 3
Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis 3
Use, tolerability, benefits and side effects of orthotic devices in Charcot-Marie-Tooth disease 1
Totale 2.561
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.847
article - articoli 9.097
book - libri 0
conference - conferenze 750
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020680 21 12 18 48 60 83 103 60 76 105 63 31
2020/2021324 14 20 7 50 19 22 50 34 27 34 22 25
2021/2022379 15 22 22 32 16 29 15 84 26 49 15 54
2022/2023508 36 51 2 54 86 64 1 51 75 4 69 15
2023/2024289 18 23 7 46 20 63 21 21 18 5 20 27
2024/202527 27 0 0 0 0 0 0 0 0 0 0 0
Totale 2.561